LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTEGUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER

• DOI: 10.1016/s1569-9056(08)60904-5
• Publication Date: 2008-03-14T14:16:12Z
• Authors: R.J. Sylvester; M.A. Brausi; W. Hoeltl; P.H. Powell; P. Whelan; T. Gorlia; T.M. De Reijke
• Keywords: 03 medical and health sciences; 0302 clinical medicine